Inpatient glucose management for arthroplasty patients
Recognition and Treatment of Dysglycemia in Elective Knee and Hip Arthroplasties. AGS - Acute Glucose Service
This study is testing a new program to help manage blood sugar levels in patients having knee and hip surgeries to see if it can improve their recovery and reduce complications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Joint Authority for Päijät-Häme Social and Health Care Academic / other |
| Locations | 1 site (Lahti) |
| Trial ID | NCT03306810 on ClinicalTrials.gov |
What this trial studies
The Acute Glucose Service (AGS) is designed to manage glucose levels in patients undergoing elective knee and hip arthroplasties. This interventional program involves a team of nurse practitioners and physicians who assess and treat dysglycemia before, during, and after surgery, while also providing ongoing education to hospital staff. The study compares outcomes of 600 patients, with a focus on improving survival rates and reducing complications related to dysglycemia. Patients will be followed for up to five years to evaluate the effectiveness of the AGS in managing glucose levels and overall health outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old scheduled for elective knee or hip arthroplasty.
Not a fit: Patients who are unable to provide informed consent or assess their quality of life will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival rates and reduce complications for patients undergoing arthroplasty.
How similar studies have performed: Other studies have shown that structured glucose management can lead to improved outcomes in surgical patients, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged \> 18 years * Elective knee and hip arthroplasty patients Exclusion Criteria: * Patients who are incompetent to give informed consent * Patients who are incompetent to assess their Quality-of-Life personally
Where this trial is running
Lahti
- Päijät-Häme Central Hospital — Lahti, Finland (Recruiting)
Study contacts
- Principal investigator: Marianne Ylikoski, MD — Päijät Häme Central Hospital
- Study coordinator: Marianne Ylikoski, MD
- Email: marianne.ylikoski@phhyky.fi
- Phone: +358447195268
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.